Description
The presence of a KRAS gene mutation is a predictor of lack of response to anti-EGFR antibody therapy in patients with metastatic colorectal cancer, as well as lack of response to targeted therapy in patients with non-small cell lung cancer.
Period of execution
Within 12 days. The specified time does not include the day of biomaterial collection
Biomaterial type
- Tissue sample
- Tissue sample in paraffin block